Vera Therapeutics (VERA)
(Delayed Data from NSDQ)
$37.39 USD
-0.23 (-0.61%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $37.41 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Vera Therapeutics, Inc. [VERA]
Reports for Purchase
Showing records 1 - 20 ( 58 total )
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Making Progress Toward ORIGIN 3 Enrollment [1Q24 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As Progress Towards ORIGIN 3 Continues, An Uneventful 4Q23 Report
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2b ORIGIN Data Shows Unprecedented Stable eGFR at 72 Weeks With Sustained Gd-IgA1, Hematuria, and UPCR Reductions
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Vera Adds $25M to Cash Reserves With Loan Draw-Down
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for VERA 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap; Phase 2b ORIGIN OLE Data On Target in 1Q24; Phase 3 ORIGIN 3 Complete Enrollment Expected in 2H24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sticking With The Sidelines While ORIGIN 3 Moves Forward
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The IgAN Era Continues, While Xphozah Makes A Splash Ahead Of Launch
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Kidney Week 2023 - Gearing Up For What''s New in Glomerular Disease
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Longer-Term Atacicept Data at ASN Likely to Add Further Support Following Final 36-Week Data at ERA; Raise PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Vera Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- ERA Highlights: ORIGIN Week 36 Data, Additional TVTX PROTECT Data
Provider: Wedbush Securities Inc.
Analyst: CHICO L